2022-2029 年臨床微生物學全球市場

市場動態

全球臨床微生物學市場的增長受到某些因素的推動，例如傳染病的上升和公眾意識的提高。

在分子水平上了解慢性病和開發治療解決方案的需求日益增長，預計將在預測期內推動市場發展，更多組織資助研發計劃。

根據美國疾病控制和預防中心 (CDC) 的數據，2020 年美國將有大約 7,860 例新的結核病病例、大約 30,000 例萊姆病新病例和大約 30,000 例腦膜炎球菌病新病例。已註冊 375 人。

同樣，根據美國癌症協會的數據，2021 年美國將有大約 190 萬例新診斷的癌症病例。因此，將實驗室檢測作為主要診斷工具之一的疾病的高流行率預計將在未來促進市場增長。埃博拉病毒和寨卡病毒等傳染性病原體的爆發也導致傳染病流行率上升。根據發表在《臨床微生物學雜誌》上的一篇文章，在醫學和微生物學實驗室中，處理和解釋樣本和標本的訓練有素和熟練的專業人員供不應求。此外，美國醫學實驗室技術人員培訓項目的數量和畢業學生的數量正在直線下降。

在高收入國家加緊努力抗擊醫院感染的同時，低收入和中等收入國家也意識到了這一威脅。預計自動化系統和創新設計的引入將在預測期內增加市場競爭並改變市場動態。這一因素正在推動預測期內的市場增長。

世界衛生組織 (WHO) 在埃塞俄比亞、布基納法索、尼日利亞、阿爾及利亞和塞內加爾等國家尤為活躍，這些國家的 HAI 發病率介於 2.5% 和 14.8% 之間。因此，這些國家對 HAI 診斷的需求不斷增長。印度、斯裡蘭卡、巴基斯坦和不丹等國家也在積極參與 HAI 宣傳計劃。印度和中國預計將成為未來推動對 HAI 診斷設備和測試需求的主要國家。這一因素也推動了預測期內的市場增長。

同樣，診斷實驗室鏈的整合和公眾意識的提高等因素也推動了市場的增長。新興市場預計將超過美國和歐洲國家。這主要是由於大型連鎖醫院在大城市開設新中心以及政府支出增加。

缺乏對微生物檢測方法的報銷可能會阻礙市場增長

但是，目前在印度、中國以及中東和非洲的其他新興經濟體等目標患者群體眾多的國家/地區，臨床微生物檢測程序的報銷不足。這是患者和醫療保健專業人員對臨床微生物學產品的偏好的主要限制因素。這將對預測期內的市場增長產生負面影響，因為它將直接影響採用高價臨床微生物產品。

COVID-19 影響分析

最近爆發的 COVID-19 大流行對市場的增長產生了負面影響，因為實驗室忙於 COVID-19 測試並停止了所有其他測試。這一因素將阻礙預測期內的市場增長。

行業分析

全球臨床微生物學市場根據波特五力分析、供應鏈分析、監管分析和定價分析等各種行業因素對市場進行了深入分析。

全球臨床微生物學市場報告提供大約 40 多個市場數據表、45 多個圖表和 180 頁結構。

內容

第1章研究方法與範圍

• 調查方法
• 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

• 按產品類型劃分的市場細分
• 按應用劃分的市場細分
• 按地區劃分的市場細分

第 4 章市場動態

• 市場影響因素
  • 驅動程序
    • 感染增加
    • 提高社會認可度
  • 限制因素
    • 在許多國家/地區，臨床微生物學費用並未全額報銷。
• 影響分析
• 商機

第5章行業分析

• 波特五力分析
• 供應鏈分析
• 監管分析
• 定價分析
• 產品分析
• 售後服務分析

第 6 章按產品類型分析

• 試劑
• 實驗室儀器
  • 孵化器
  • 克過濾器
  • 菌落計數器
  • 高壓滅菌器
  • 培養皿灌裝機
• 自動培養系統
  • 微生物檢測設備
  • 分子生物診斷設備
  • 顯微鏡
  • 質譜儀

第 7 章按應用程序

• 呼吸系統疾病
• 血液感染
• 消化系統疾病
• 其他

第 8 章按地區

• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 其他歐洲地區
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 其他亞太地區
• 中東和非洲

第 9 章競爭格局

• 競爭場景
• 市場情況/份額分析
• 併購分析

第 10 章公司簡介

• 生物梅裡埃公司
  • 公司簡介
  • 產品組合和描述
  • 主要發展狀況
  • 財務摘要
• Danaher Corporation, Becton
• Dickinson and Company
• Abbott Laboratories
• Bio-Rad Laboratories, Inc
• , F. Hoffmann-La Roche AG
• Bruker Corporation
• Hologic, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.（*List is not exhaustive）

第11章 DataM

Market Overview

Clinical microbiology market size was valued at US$ 3.9 billion in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 6.5% during the forecast period (2022-2029).

Clinical microbiology focuses on all aspects of patient infections from testing samples to identifying bacterial, viral, fungal, and parasitic agents that are contributing to the infectious process, determining the susceptibility of microorganisms to various antimicrobial agents, and reporting the results to healthcare providers.

The adaptation of microbiological techniques to the study of the etiological agents of infectious disease. Clinical microbiology determines the nature of the infectious disease and tests the ability of various antibiotics to inhibit or kill the isolated microorganisms. In addition to bacteriology, a contemporary clinical microbiologist is responsible for a wide range of microscopic and cultural studies in mycology, parasitology, and virology. The clinical microbiology is often the most competent person available to determine the nature and extent of hospital-acquired infections, as well as public-health problems that affect both the hospital and the community.

Market Dynamics

The global clinical microbiology market growth driven by certain factors such as by rise in infectious diseases, increase in public awareness are among the key factors driving the market growth.

Increasing need to understand chronic diseases at a molecular level and develop therapeutic solutions to encourage these organizations to fund research and development programs., is expected to drive the market during the forecast period

According to the Centers for Disease Control and Prevention (CDC), around 7860 new cases of tuberculosis, 30,000 new cases of Lyme disease, and 375 new cases of meningococcal disease were registered in the U.S. in 2020.

Similarly, according to the American Cancer Society, around 1.9 million new cases of cancer were diagnosed in the U.S. in 2021. Thus, the high prevalence of diseases where clinical tests are used as one of the major diagnostic tools is expected to augment market growth in the future. Sudden outbreaks of Ebola, Zika, and other contagious pathogens are also contributing to the rising prevalence of infectious diseases. As per an article published in the Journal of Clinical Microbiology, there is a shortage of trained and skilled professionals in medical and microbiological laboratories for processing and interpreting samples and specimens. Moreover, there has been a steep decline in the number of medical laboratory training programs and students graduating from such programs in the U.S.

As high-income countries are stepping up their pursuit of countering hospital-acquired infections, middle- and low-income countries are recognizing the threat. The introduction of automated systems and innovative designs is expected to intensify market competition and change market dynamics over the forecast period. This factor is driving the growth of the market in the forecast period.

The World Health Organization (WHO) is particularly active in countries such as Ethiopia, Burkina Faso, Nigeria, Algeria, and Senegal, where the occurrence of HAIs ranged between 2.5% and 14.8%. This has led to increased demand for HAI diagnostics in these countries. Countries such as India, Sri Lanka, Pakistan, and Bhutan are also actively participating in HAI awareness programs. India and China are projected to be the main countries driving demand for HAI diagnostics instruments and tests in the future. This factor is also driving the growth of the market in the forecast period.

Similarly, factors like the consolidation of diagnostic laboratory chains and the increase in public awareness are driving the growth of the market. The emerging countries are expected to outperform the U.S. and European countries. This is mainly due to the increase in the major hospital chains opening new centers in major cities as well as an increase in government expenditure.

Lack of reimbursement of microbiology testing procedures are likely to hamper the market growth

However, Clinical microbiology testing procedures are not adequately reimbursed across several countries such as India, China, and other emerging countries in the Middle East and Africa, which have a high target patient population base. This is a major factor that limits the preference for clinical microbiology products among patients and healthcare professionals. This directly affects the adoption of premium-priced clinical microbiology products, thereby negatively affecting their market growth in the forecast period.

COVID-19 Impact Analysis

The recent outbreak of the COVID-19 pandemic is negatively affecting the growth of the market as the laboratories are busy with the COVID-19 test which has halted all other tests. This factor will hinder the growth of the market in the forecast period.

Industry Analysis

The global clinical microbiology market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, supply chain analysis, regulatory analysis, pricing analysis etc.

Segment Analysis

The laboratory instruments segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The global clinical microbiology market is segmented based on product type by laboratory instruments which are further sub-segmented into incubators, gram strainers, bacterial colony counters, autoclave sterilizers, petri dish fillers, and automated culture systems which is further sub-segmented into microbiology analyzers, molecular diagnostic instruments, microscopes, mass spectrometers, and reagents. The reagents segment held the largest market share. Factors such as the higher cost of specialized kits and constant repeat purchase are expected to drive the segment over the forecast period. A reagent s a substance or compound added to a system to cause a chemical reaction, or added to test if a reaction occurs. The importance of reagents will continue to outstrip supplies in many places as the race for safe and effective vaccines and treatment. A reagent may be used to tell whether or not a specific chemical substance is present by causing a reaction to occur with it.

The laboratory instruments segment is expected to have a positive market. Laboratories require a variety of equipment and consumables to perform tests and research activities. These are found in different types of laboratories such as research labs, clinical diagnostic labs, pathology labs, microbiology labs, educational labs, etc. to carry out research, scientific experiments, and execute analyses of different scientific materials.

It is estimated that the laboratory instrument segment is expected to witness significant growth over the forecast period, owing to technological advancements in the field of laboratory equipment, an increase in the number of clinical diagnostic procedures, and a rise in private & public healthcare investments. Besides, favorable insurance policies related to laboratory equipment further supplement the market growth. Furthermore, an increase in research related to life science and biotechnology boosts the laboratory instruments segment

Increasing chronic diseases such as chronic respiratory diseases, cardiovascular diseases, and diabetes, and increasing incidence of lifestyle diseases such as heart disease, obesity, atherosclerosis and hereditary diseases such as hemophilia, Down's syndrome, cystic fibrosis, and sickle cell anemia are leading to the increasing demand of laboratory equipment to bring innovative technologies in the market. According to the World Health Organization (WHO), the non-communicable disease leads to cause 40 million deaths each year, which is equivalent to 70% of all deaths worldwide. Cardiovascular diseases account for most of NCD mortality (17.7 million) annually, followed by cancer (8.8 million), respiratory disease (3.9 million), and diabetes (1.6 million). Thus, these factors will drive the growth of the market in the forecast period.

Further, the market is also classified based on application as respiratory diseases, bloodstream infections, gastrointestinal diseases, and others. The respiratory diseases segment is held the largest market share. The rise in prevalence of respiratory infectious diseases, such as Coronavirus diseases, MERS, chronic obstructive pulmonary disease, tuberculosis, pertussis, and influenza, is projected to drive the segment.

According to data published in January 2020, 2519 laboratory-conformed cases of Middle East respiratory syndrome (MERS), were reported, which includes 866 associated deaths globally. The majority of cases reported were from Saudi Arabia (2121 cases), including 788 related deaths with a higher fatality rate of 37.1%.

Moreover, the emergence of the COVID 19 pandemic has driven the segment. According to statistics, as of April 2020, there were around 3.45 million cases of COVID-19 globally, which drives the respiratory diseases segment. This factor will drive the growth of the market in the forecast period.

Geographical Analysis

North America region holds the largest market share of the global clinical microbiology market

North America dominated the global surgical glue market and is expected to grow at the highest CAGR during the forecast period due to an increase in the burden of COVID-19, well-developed health care infrastructure, and increasing prevalence of chronic obstructive pulmonary diseases, flu diseases, whooping cough, and other respiratory infections. This is anticipated to augment the Respiratory infectious disease treatment market in the region. COPD is considered to be the third-leading cause of death in the U.S., and the fourth-leading cause of death across the world. According to an article published on Very well Health, COPD affects around 11 million people in the U.S. and occurs in people over the age of 40. These statistics drive the demand for the treatment of respiratory infectious diseases. This factor will drive the growth of the market in the region.

Competitive Landscape

The global clinical microbiology market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market bioMerieux SA, Danaher Corporation, Becton, Dickinson and Company, Abbott Laboratories, Bio-Rad Laboratories, Inc, F. Hoffmann-La Roche AG, Bruker Corporation, Hologic, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc. are the leading market players with significant market share.

Key Companies to Watch

Bio-Rad Laboratories

Overview: Bio-Rad Laboratories, Inc. is an American company that continued to produce innovative and useful products in the healthcare industry that assist life science researchers in accelerating the discovery process, and medical diagnostic labs obtain faster better results.

Product Portfolio: DC Protein Assay Reagents Package- Reagent pack for colorimetric assays, includes 250 ml alkaline copper tartrate, 2 L dilute Folin reagent, 5 ml surfactant solution; 450 assays.

The global clinical microbiology market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Product Type
• 3.2. Market Snippet by Application
• 3.3. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. A rise in infectious diseases
    • 4.1.1.2. Increase in public awareness
  • 4.1.2. Restraints
    • 4.1.2.1. Clinical microbiology testing procedures are not adequately reimbursed across a number of countries
• 4.2. Impact Analysis
• 4.3. Opportunity

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis
• 5.4. Pricing Analysis
• 5.5. Product Analysis
• 5.6. Post Sales Services Analysis

6. By Product Type

• 6.1. Introduction
• 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
• 6.3. Market Attractiveness Index, By Product Type
  • 6.3.1. Reagents *
    • 6.3.1.1. Introduction
    • 6.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2020-2028
  • 6.3.2. Laboratory Instruments
    • 6.3.2.1. Incubators,
    • 6.3.2.2. Gram strainers
    • 6.3.2.3. Bacterial colony counters
    • 6.3.2.4. Autoclave sterilizers
    • 6.3.2.5. Petri dish fillers
  • 6.3.3. Automated Culture Systems
    • 6.3.3.1. Microbiology Analyzers
    • 6.3.3.2. Molecular diagnostic instruments
    • 6.3.3.3. Microscopes
    • 6.3.3.4. Mass Spectrometers

7. By Application

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
• 7.3. Market Attractiveness Index, By Application
  • 7.3.1. Respiratory Diseases
    • 7.3.1.1. Introduction
    • 7.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3.2. Bloodstream Infections,
  • 7.3.3. Gastrointestinal Diseases
  • 7.3.4. Others

8. By Region

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
• 8.3. Market Attractiveness Index, By Region
• 8.4. North America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. The U.S.
    • 8.4.5.2. Canada
    • 8.4.5.3. Mexico
• 8.5. Europe
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. Germany
    • 8.5.5.2. The U.K.
    • 8.5.5.3. France
    • 8.5.5.4. Rest of Europe
• 8.6. South America
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.6.5.1. Brazil
    • 8.6.5.2. Argentina
    • 8.6.5.3. Rest of South America
• 8.7. Asia Pacific
  • 8.7.1. Introduction
  • 8.7.2. Key Region-Specific Dynamics
  • 8.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 8.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.7.5.1. China
    • 8.7.5.2. India
    • 8.7.5.3. Japan
    • 8.7.5.4. Australia
    • 8.7.5.5. Rest of Asia Pacific
• 8.8. The Middle East and Africa
  • 8.8.1. Introduction
  • 8.8.2. Key Region-Specific Dynamics
  • 8.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 8.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

• 10.1. bioMerieux SA*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio and Description
  • 10.1.3. Key Developments
  • 10.1.4. Financial Overview
• 10.2. Danaher Corporation, Becton
• 10.3. Dickinson and Company
• 10.4. Abbott Laboratories
• 10.5. Bio-Rad Laboratories, Inc
• 10.6. , F. Hoffmann-La Roche AG
• 10.7. Bruker Corporation
• 10.8. Hologic, Inc.
• 10.9. QIAGEN N.V.
• 10.10. Thermo Fisher Scientific Inc. (*List is not exhaustive)

11. DataM Intelligence

• 11.1. Appendix
• 11.2. About Us and Services
• 11.3. Contact Us